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1. Introduction
Osteoarthritis (OA) is a progressively degenerating joint disease. The prevailing paradigm
suggests that OA results from an impaired regeneration ability of the damaged cartilage due
to biomechanical and biochemical changes. There is an increasing recognition that OA is a
disease of the joint as an organ involving all intraarticular tissue i..e. subchondral bone,
synovium, cartilage, menisci, ligaments. Therefore, changes as increased metabolism and
sclerosis of the subchondral bone, chondrocyte death and extracellular matrix (ECM) catabo‐
lism, as well as primary or secondary changes in the synovium (including endothelial cell
proliferation, macrophage infiltration and inflammation) will induce alterations in the
molecular composition of the synovial fluid. The clinical signs associated with these changes
include pain, rigidity and decreased functionality, which may compromise overall health and
quality of life [1].
The prevalence of OA is very high, expected to affect more than 50 million subjects in the US
by 2020, and will increase with the ageing of the population [2]. According to the American
College of Rheumatology, nearly 70% of people over age 70 have X-ray evidence of OA,
although only half ever develop symptoms [3].
The barriers to treatment development include the insufficient understanding of the pathology
and the fact that the OA physiopathology may not be identical for all patients. Several
pharmaceutical approaches (analgesics, non steroidal anti-inflammatory drugs, COX-2
inhibitors and steroids) have been proposed, with the aim of reducing pain and maintaining
and/or improving function [4]. However, none of these options has shown to delay the
progression of the disease or reverse joint damage. In addition, the incidence of adverse
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reactions to these drugs increases with age. Data from epidemiological studies consistently
show that the risk of cardio-vascular and gastro-intestinal complications is very high and
largely dose-dependent [5]. It is well known that non steroidal anti-inflammatory drugs, as
well as selective COX-2 inhibitors, may cause renal failure, hypertension and water retention
and have a thrombotic potential, especially for high doses and long term treatments [6]. On
the other hand, corticosteroids are burdened with relevant side effects, when given systemi‐
cally, and therefore are usually administered by intra-articular (IA) injection in patients who
fail to respond to other conservative measures; in particular, patients with joint effusions and
local tenderness may have greater benefit from this option. Although it has been established
that corticosteroid injections are relatively safe, there are concerns regarding their possible
adverse events following repeated treatments. These effects include local tissue atrophy,
particularly when small joints are injected, long-term joint damage, due to reduced bone
formation, and risk of infection, due to suppression of adrenocortical function [7].
Considering the limits of therapies at present available, drugs with minimal side effects, and
which can stop the progression of the disease, are therefore warranted. Research in Regener‐
ative Medicine in the last decades, has shaped new investigational biological preparations that
can be injected within the joints. These include mesenchymal stem cells (BMSCs [Bone Marrow
Mesenchymal Stem Cells] and AdSCs [Adipose Mesenchymal Stem Cells]). The initial idea of
MSC therapies was to replace damaged or death cells but moved towards using MSCs as a
tool to modify the tissue environment. The concept is based on the paracrine actions of MSCs,
hence major biological mechanisms to be targeted by these therapies are inflammation,
angiogenesis or modifications of the catabolic environment. Injectable MSCs therapies are not
capable of structurally modifying the OA joint. Due to the costs, and lack of evidences of the
regenerative potential of these cellular therapies, other less expensive and easier to implement
approaches are being investigated. These include Platelet Rich Plasma (PRP) injections or
combination products such as PRP + Hyaluronic acid (HA).
Both PRP and HA have been extensively used to improve lubrication, modulate inflammation
and modify the catabolic micro-environment. In doing so, these conservative treatments not
only aim to reduce clinical symptoms, but interfere with OA progression.
In this article we seek to summarize the current pre-clinical and clinical knowledge on this
topic, reporting comparative studies between HA and PRP injections, and suggesting the
possibility of the combined use of these therapeutic agents.
2. Hyaluronic acid
2.1. Basic concepts and experimental research
Hyaluronan is a polyanionic, unbranched glycosaminoglycan polymer composed of disac‐
charide subunits of N-acetyl-D-glucosamine and D-glucuronic acid. It was isolated for the first
time in 1934 by Karl Meyer and John Palmer from the vitreous of bovine eyes [8]. These
scientists proposed the name “hyaluronic acid” from hyaloid (vitreous) and uronic acid.
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Although the term HA is often used in the literature, the correct name reflecting the configu‐
ration of this molecule in vivo is hyaluronan. Indeed, in vivo, at physiological pH, it exists as
a polyanion and not in the protonated acid form [9,10]. In this chapter, for convenience, we
will use the term HA all through the text. HA is present in many tissues, but the larger amount
of hyaluronan resides in the dermis and epidermis. It is also an essential component of the
hyaline cartilage (1mg/g wet weight) where it organizes the ECM by creating specific interac‐
tions with aggrecan, a large chondroitin sulfate proteoglycan, present at higher concentration
(25-50 mg/g wet weight). Aggrecan and type II collagen are the main macromolecules in the
cartilage ECM. The spatial configuration of aggrecan and type II collagen are responsible of
mechanical properties of the hyaline articular cartilage.
High molecular weight (HMW) HA is also the main component of synovial fluid; it is synthe‐
sized and extruded within the synovial fluid by the lining fibroblastic cells of the joint capsule
named type B synoviocytes [10]. The volume of synovial fluid in the knee is 3-4 ml. Its role, in
addition to lubrication, is to provide nutrients to the hyaline cartilage and create a hypoxic
environment on the cartilage surface.
The physiologic turnover (i.e. catabolism balanced by production) of HA within the joint is
very dynamic; the half-life of HA is estimated in 12 hours [11]. Importantly, HA turnover, in
both the cartilage ECM and the synovial fluid, is fundamental in the maintenance of joint
homeostasis. Reticulo-endothelial cells lining the lymphatic vessels actively remove about 90%
of the HA. HA catabolism can occur through hyalurodinase actions and/or peroxidative
cleavage. It has been hypothesized that peroxidative cleavage, a process that consumes O2 and
helps to maintain the hypoxic environment within the joint, is required for normal synovial
function and joint homeostasis [12].
HA polymers are synthesized by three different synthases termed HAS (HAS-1, -2 and -3).
HMW HA has anti-inflammatory, anti-angiogenic and anti-immunogenic properties [13-16].
The high viscosity of HMW HA grants viscoelastic properties to the fluid, and along with
lubricin contributes to the boundary lubrication that is necessary for low friction levels on the
articular surface [17]. Thus, it has a shielding effect on cartilage surfaces and other joint
components.
Beside HA role in viscosupplementation and major functions in the biophysical and homeo‐
static conditions of the joint, an important aspect of HA biology to be considered is its influence
on cell behavior.
Basic research, performed in OA models in animals (rats, rabbits, dogs and sheep), has shown
that HA has several pleiotropic signaling properties (biosupplementation), such as immuno‐
suppressive, anti-inflammatory, anti-apoptotic, anti-angiogenic and anti-fibrotic effects, with
normalization of endogenous HA synthesis, and chondroprotection [16]. Actually, HA binds
to a number of cell membrane receptors termed hyaladherins. The predominant and more
widely expressed is CD44, a membrane glycoprotein made of ten stable exons and ten variable
exons inserted in different combinations at a particular extra-membrane site [16].
HA can be pro-inflammatory, however immune cells only bind HA when activated by an
inflammatory agent. Actually, CD44 is expressed in the membrane of immune cells, therefore
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HA can participate in the recruitment of neutrophils, macrophages and lymphocytes [13].
Indeed, CD44 decrease in articular cartilage is related to progression of knee OA [16].
Paradoxically, HA-CD44 binding is involved in the resolution of inflammation. Besides, both
CD44 and RHAMM (CD168) (the HA receptor for HA-mediated motility) are involved in the
regulation of growth factor (GF) signaling.
A recent study has been performed in an experimental model of murine OA (TGF-β1 injection
and treadmill running), which displays many OA-like changes, including synovial activation.
HA injection, 24 hours after TGF-β1 injection, hinders neovascularization and fibrosis of the
synovium, and keeps in good condition articular cartilage in wild-type, but not in CD44
knockout mice. This finding suggests that the injected HA enhances the synthesis of chondro‐
genic proteins, and blocks that of fibrogenic/degradative proteins in both the cartilage and
subchondral bone [18].
A further research, performed in patients with knee or hip OA, has demonstrated the presence
of activated T cells in the synovial fluid, so confirming that OA is a disease with a immuno‐
logical/inflammatory involvement. In these patients, HA injections decreased the levels of
activated T cells, and so regulated the articular milieu [19].
The analgesic properties of HA, besides to the activities previously described, could be also
attributed to a specific activity on opioid receptors [20]. Pain in OA is likely to have multiple
sources, including subchondral bone marrow lesions, synovium and the periostium as well as
soft tissues surrounding the joint, including extra-articular bursae and fat pad. Pain in OA is
classified as nociceptive, based on the presence of opioid receptors in the synovial lining and
sublining cells. Various molecules present in extracellular space modulate nociceptor sensi‐
tivity by targeting different receptor types. The biological mechanisms responsible for HA
analgesic activity have been partially elucidated by Zavan et al. [20] in experiments performed
with Chinese Hamster Ovary cells that express a panel of opioid receptors. The results
demonstrated that HA stimulates the k receptor (KOP), also expressed on fibroblast-like
synoviocytes, in a concentration dependent manner, but not the DOP, MOP and NOP
receptors. This selective activity could be due to the singular conformational structures of HA
compared to morphine, more closely related to dynorphin organization. The pain threshold
also increases, due to the direct analgesia through inhibition of pain receptors, and by a direct
action on synovial nerve endings and stimulation of synovial lining cells.
At present, HA compounds with different molecular weight (MW) are commercially available.
The enhanced diffusion of LMW preparations (0.5-1.5 millions Dalton) through the ECM of
the synovium makes possible the interaction with synovial cells [21]. However, because of the
modest elastoviscosity of these compounds, compared to native hyaluronan in the synovial
fluid, HA preparations with HMW (6-7 millions Dalton), have been developed. These formu‐
lations retain higher amounts of fluid in the articular space using their hydrophilic properties,
and also have a greater anti-inflammatory activity, as shown by reduced prostaglandin E 2
and bradykinin concentration attributed to a reduced migration of inflammatory cells [22].
Currently, many types of particulate carriers have been investigated aiming to increase the
retention time of the therapeutic agents within the joint capsule. Among them, cationic
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polymeric nanoparticles form ionically connected filamentous arrangements (“ionically cross-
linked hydrogels”) linked with local hyaluronan [23]. After intra-articular (IA) injection in rat
knees about 70% of these hydrogels are retained into the joint for 1 week. Thus, cationic
polymeric nanoparticles increase HA retention into joints and are suitable for therapeutic use.
Another medical device combines chondroitin sulphate and HA [24]. The role of chondroitin
sulfate is twofold: a) to create specific interactions designed to optimize HA rheological
behavior; and b) to regulate cartilage metabolism by performing as a substrate for polysulph‐
ated glycosaminoglycans synthesis, as well as inhibiting the synthesis of catabolic cytokines
and metalloproteinases.
To ameliorate OA treatment while avoiding adverse effects, a mixture of celecoxib-loaded
liposomes embedded in HA gel has been formulated [25]. Celecoxib is a COX-2 selective
inhibitor with analgesic and anti-inflammatory properties. Liposomes are good candidates for
local delivery of therapeutic agents because they are derived from naturally occurring
biodegradable and nontoxic lipids. The combination of the two drugs, both efficient in the
treatment of OA, but with different mechanisms, injected into the joints, is expected to have
synergistic effect. Indeed, in a rabbit knee OA model, the liposomal combination was more
effective than a single drug in pain control and cartilage protection, as shown by histopatho‐
logical studies [26].
Preliminary studies suggest positive results using an innovative viscosupplement (SynolisV-
A) produced from high a concentration of HA, combined with a high concentration of sorbitol
as a free radical scavenger (single injection of 4 ml in total), in subjects with symptomatic hip
OA [27].
These pharmaceutical studies taken together show how intense is nowadays the research
aiming to ameliorate the therapeutic efficacy of HA. Open-label, non controlled studies have
proven the clinical efficacy of some of these products. However, high quality clinical studies
proving their superiority towards the available preparations of HA are still lacking.
2.2. Clinical trials
2.2.1. Knee
Viscosupplementation with HA in knee OA has been approved by the FDA and is recom‐
mended by OARSI for non-severe OA. Guidelines are based on a meta-analysis of randomized
saline-controlled trials, including a total of 29 studies representing 4866 unique subjects (IA
HA: 2673; IA saline: 2193) [28].
Prospective single or double-blind trials have been done using different types of HA. The
number of injections varied from 3 to 5 weekly, with a maximum of 11 in 23 weeks, the doses
ranged from 15 to 60 mg, and follow-up periods ranged from 4 weeks to 18 months. Pain
outcomes were followed using the Visual Analogic Scale (VAS) and Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC). A minor number of studies evaluated
the functional outcomes (WOMAC, Lequesne Index, Range of motion [ROM]), the subjective
global assessment and the quality of life of the patients.
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HA injection resulted in very large treatment effects between 4 and 26 weeks for knee pain
and function compared to pre-injection values. Compared to saline controls, standardized
mean difference values with IA HA ranged from -0.38-0.43 for knee pain and +0.32-0.34 for
knee function. Clinical changes were similar in the trials where LMW or HMW HA was used.
However, the number of injections was lower for HMW preparations, and this is an important
advantage for the patients and the clinician. There were no statistically significant differences
between IA HA and saline controls in any safety outcomes, including serious adverse events,
and study withdrawal. The authors concluded that IA HA injections are safe and effective in
patients with symptomatic knee OA [28].
Another meta-analysis [29], comparing the time course of symptoms (the “therapeutic
trajectory”) in HA and corticosteroid treated patients, highlights that, from baseline to week
4, IA corticosteroids were more effective than HA. By week 4, the two approaches had equal
efficacy, but beyond week 8 HA was superior.
It must be noted that, in all trials, some of the patients were non-responders to therapy.
Currently, the characteristics of responders have not been clearly identified, but a greater
benefit was observed in patients with low grade OA (Kellgren and Lawrence [KL] grade I-II)
[9]. This is indirectly confirmed by changes of the serum levels of specific OA biomarkers
(Coll2-1 and Coll2-1 NO2) after viscosupplementation. The serum concentrations of these
biomarkers were significantly higher in KL grade III/IV patients compared to KL grade I/II
patients, and were significantly lower at baseline in responders than in non-responders [30].
Therefore, a rapid decrease of type II collagen degradation and joint inflammation after HA
injection supports the utility of serum biomarkers as predictive factors for response to
treatment. The role of age in predicting the therapeutic response is debated: some authors
report no significant difference among subjects of different ages, whereas others claim that IA
joint HA injections are effective in both young and old patients with regard to pain and
functional status over a short-term period, but that, in the long term (12 months), the benefit
declines rapidly in the elderly subjects [15]. Essentially, advanced OA may be a non-return
back irreversible condition.
2.2.2. Hip
The number of studies about viscosupplementation of hip OA is limited when compared with
knee OA. The reasons can be the deeper localization of this joint, and the proximity of femoral
vessels and nerves, which makes mandatory performing the injections under imaging control
[31]. Moreover, the level of evidence for most of these trials is low, because they are cohort
studies and lack of a reference group [9].
In these studies, several HA compounds were used. The number of injections ranged from 1
to 3 for each patients, and only in few cases 4 or 5 injections were performed. In general, the
injections number was lower for HMW preparations. The length of treatments and the outcome
measures were similar to those used in knee randomized controlled trials. All the trials have
shown a reduction of pain, which, in general, becomes evident within 3 months and persists
in the following 6, 12 and 18 months. Besides the reduction of pain, also the articular function
(Harris Hip Score, WOMAC score, Lequesne Index, and American Academy of Orthopaedic
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Association Lower Limb Core Scale) was improved [9,15]. Moreover, an improvement of
kinematic and kinetic parameters in walking pattern at 6 months (higher cadence, stride length,
significant increase for the pelvic tilt at heel contact and for hip flexion-extension moment at
loading response sub-phases of gait cycle) has been shown by a recent study [32]. Interestingly,
the IA injection of both LMW and HMW HA has been proven efficacious in delaying the total
hip replacement in patients affected by symptomatic hip OA [33,34].
A further observation, which confirms the previous data, is the reduction of non steroidal anti-
inflammatory drugs consumption [35].
2.2.3. Ankle
In the few studies performed in ankle OA, patients suffering from post-traumatic KL grade II-
IV ankle OA were enrolled. Different HA preparations were used, and patients received 1 up
to 5 injections. Clinical benefit was evaluated by means of different scales (VAS, Ankle
Osteoarthritis Scale, American Orthopaedic Foot and Ankle Society, Short Form-12, Short
Form-36, WOMAC), and the follow-up period varied from 6 to 18 months [36].
An improvement in all the outcome measures was reported, with the effect lasting for 18
months. However, it is not clear from reports whether the pain reduction was clinically
significant, or could be ascribed only to a placebo effect. In addition, the lack of controls does
not allow definitive conclusions on the efficacy of HA.
The level 1 evidence studies are more qualified to assess the therapeutic efficacy, but also these
trials show several limitations (e.g., no information on the actual number of potential patients,
no clear randomization, imbalance of baseline characteristics between intervention and control
groups, statistical weakness), and therefore have to be considered as low quality. The patients
treated with HA showed a significant decrease in pain and disability at 6 months, with the
effects lasting 12-13 months [37, 38].
Besides the reduction of these parameters, an improvement in ankle sagittal ROMs, and gait
quality was observed. However, it must be noted that in any study the authors found difference
between HA and controls groups. In particular, in the studies performed by Salk [38], Cohen
[39] and DeGroot [37], the patients, treated with a 1-2.5 ml phosphate-buffered saline solution
injection, reported a similar improvement in all parameters evaluated. Analogously, positive
results were observed in patients, who followed a 6 weeks exercise therapy (muscle strength‐
ening and ankle ROM exercises) [40], and after arthroscopic lavage of OA ankle joint [41].
Recent observations aimed to identify the baseline prognostic factors of outcome have shown
that early stage disease and duration of pain less than 1 year are independent predictors
associated with higher satisfaction at 3 and 6 months after treatment [42]. However, this
assumption has been challenged by Lucas et al. [43], who have observed that viscosupple‐
mentation had a significant positive effect after a very long observation period (45.5 months),
and that neither etiology nor severity of OA was predictive of the response.
On the basis of these observations, the efficacy of HA in reducing pain and improving function
in ankle OA is still debated. Several factors can explain these discrepancies. Ankle joint,
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anatomically and functionally, is more complex than other joints, which are usually treated
with positive results with HA (hip, knee) [36].
Finally, it must be considered that the majority of studies has been performed blindly and only
few under imaging guidance [36]. This can be a valid explanation of several unsatisfactory
results, because there is evidence that about one third of IA injections are not delivered into
the IA cavity, when performed without a visual aid [44]. At this regard, ankle joint presents
many technical difficulties of injecting IA, due to its complex anatomy, further complicated
from the OA joint changes.
2.2.4. Shoulder
HA is effective and well tolerated for the treatment of OA and persistent shoulder pain
refractory to other standard non operative interventions. Both 3 and 5 weekly IA injections of
LMW HA provide significant improvement in terms of shoulder pain (VAS score on move‐
ment), with the effects lasting 7-26 weeks [9].
Similarly, in a 6 months follow-up study, a significant reduction in VAS pain score was also
provided with 3 weekly IA HMW HA (Hylan G-F 20) injections [45]. In addition, most of the
patients experienced an improvement in the shoulder function scores (Oxford Shoulder Score
and Constant-Murley Score) and in the activities of daily living.
Studies  comparing  Hylan  G-F  20  versus  6  methylprednisolone  acetate  [46]  or  versus
physiotherapy [45] show that HA is effective in reducing pain for up to 6 months, whereas
the positive results observed after corticosteroid or physiotherapy have a shorter efficacy
and decline after 1 or 2 months. However, these positive results are challenged by a double-
blind, randomized, controlled multicenter trial, where patients who received 3 weekly HA
injections did not report any significant difference in term of pain reduction at 26 weeks
when compared with placebo [47].
2.2.5. Other joints
The efficacy of HA has been investigated in the treatment of carpo-metacarpal OA, and positive
results have been reported by most of the authors [9]. In particular, an early improvement in
VAS score was observed after 2 weeks post treatment, with the effects lasting until 1-3 months.
The long term effects of HA were demonstrated only in few studies, in which the pain relief
was reported at 6 months [48]. Beside pain reduction, also grip strength improved significantly,
although this effect was achieved slowly, with better results observed at 6 months. Moreover,
the local inflammation measured by means of Power Doppler exam significantly decreased
after 2 weeks of treatment [49].
Similar positive results have been reported in the treatment of temporo-mandibular OA (with
or without effusion). The superiority of HA injections (associated or not with arthrocentesis)
was shown only against placebo saline injections, whereas outcomes were comparable with
those achieved with corticosteroid injections [50-53]. Interestingly, in an experimental model
of arthropatic temporo-mandibular joint, El-Hakim and Elyamani [54] found, after repeated
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IA injections, an increase in the thickness of the cartilagineous layer, suggesting that HA can
inhibit the progression of OA changes. A recent study, aiming to identify predictors for
treatment efficacy, has shown that only unilateral temporo-mandibular joint OA predicts
better the benefit [55], while sex, age, pain duration are not provided of predictive power.
In the treatment of elbow OA the results are inconclusive [9,15]. Positive effects have been
observed only in two small studies, while, in a larger study (18 patients), IA HA was not
effective in the treatment of post-traumatic OA of the elbow.
Controversial results have been observed also in the treatment of spine OA. Fuchs et al. [56]
reported significant pain relief and improved quality of life, also in the long term, in patients
affected from facet joints OA with chronic non-radicular pain in the lumbar spine. However,
these results are not in agreement with a recent study by Cleary et al. [57], who have not shown
any benefit of viscosupplementation in the management of symptomatic lumbar facet OA.
Finally, it is worth of note that the side effects of HA are negligible. In quite all the clinical
trials, no general side effects were observed, and only few patients reported a sensation of
heaviness and pain in their joint after injection [9]. These effects were more frequent in studies
performed in blind conditions compared to those performed under imaging guidance. No
differences were observed in relation to HA preparation used or to the number of injections
[9]. Side effects usually disappeared after 2-7 days without any therapeutic intervention and
did not limit basic or instrumental activities of daily living. Vascular or nervous complications
were never reported, neither gout, chondrocalcinosis, sometimes observed after viscosupple‐
mentation of the knee [15]. Septic arthritis or aseptic synovial effusion occurred in a very
limited number of cases [58].
3. Platelet rich plasma
Assuming that tissue repair involves the sequential signaling of multiple factors, and therefore
the delivery of a single type of molecule is insufficient, the use of PRP is gaining ground
focusing on the concept that the co-delivery of various proteins can break the vicious circle
based on failure of the repair process that progressively leads to OA.
Indeed, the PRP therapeutic activity is to release a collection of signaling proteins, including
growth factors (GFs) and chemokines, among other proteins, to the joint environment, thereby
inducing tissue regeneration mechanisms [59-61]. Briefly, regulatory proteins released from
PRP must be capable of interfering with the catabolic microenvironment in OA joints while
modulating the inflammatory response, inducing cell migration and proliferation, and
regulating angiogenesis and cell differentiation. Since PRPs can have a broad range of
functions, it is difficult to decide which function or aspect is the most relevant for OA outcome.
A full description of signaling proteins released from PRP and their role in modulating
inflammation and vascular pathology have been recently appraised in a personal review [59].
Here we focus on describing the properties of PRP on mechanisms that help in building the
rationale for creating a combined HA/PRP treatment.
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3.1. Precursor cell migration, proliferation and differentiation
Precursor cell migration, proliferation and differentiation are intended biological effects
theoretically related to the PRP clinical response. Cartilage is composed of post-mitotic cells
incapable of proliferation. Therefore, regeneration may be based on migration of mitotic stem
cells or their progeny (precursor cells) to the cartilage surface, followed by differentiation and
the synthesis of ECM components. However, avascular nature of cartilage hinders migration
of circulating stem cells, thus precursor cells identified in other joint tissues such as the
synovium or the Hoffa fat, although with distinct differentiation potency, are candidates to
repair cartilage defects; alternatively cells can home cartilage lesions by migrating from the
subchondral bone when arthroscopic drilling is performed [62].
3.1.1. Cell migration
PRP exploits the ability of cells to migrate. Actually, by inducing changes in the cell microen‐
vironment, PRP facilitates the motility of BMSCs, Adipose-Derived Stem Cells (ADSCs) and
chondrocytes. The ability of PRP to create gradients of GFs and chemokines is based on three
central features: first, on the kinetics of release of chemokines from α-granules in platelets,
second on the structural and chemical properties of the fibrin scaffold, and finally on the
plasmin degradation of the fibrin [63,64].
Platelets release upon activation a huge repertoire of chemokines, GFs and other cytokines
prestored in their α-granules. In parallel upon PRP activation, a specialized provisional fibrin
network is formed. Fibrin binds several plasma proteins including vitronectin, fibronectin,
Von Willebrand factor (vWF), and thrombospondin. Recent research has identified fibronectin
as a major factor in human serum to recruit subchondral progenitor cells [65]. Additionally,
these proteins within the fibrin bind GFs and form molecular complexes that can dramatically
enhance the potency of GFs.
Besides these effects PRP stimulates HA synthesis, as shown by in vitro experiments performed
on synovial fibroblasts isolated from the synovium of patients with OA undergoing prosthetic
surgery, and the newly synthesized HA may help to improve cell motility [66,67].
3.1.2. Cell proliferation
PRP also supports other mechanisms necessary for cartilage repair (i.e. proliferation) [68]. In
fact, PRP has been deeply tested and shown to be a safe and suitable supplement to achieve
large scale expansion of MSCs for cell therapy purposes. Moreover, PRP not only supports
MSCs proliferation, but it is safer and more effective than fetal bovine serum (the typical serum
supplement used to expand cells). However, there is no consensus on which PRP formulation
is more proliferative: the PRP releasate or the platelet lysate. The former is the supernatant
extruded after PRP coagulation, and it may be considered as a PRP serum; the activation
method to achieve granule secretion may introduce variability between products [59,69,70].
Alternatively, the platelet lysate is obtained after several freeze/thaw cycles of either PRP or
Leukocyte-PRP (L-PRP) [71-73].
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Importantly, studies demonstrate that MSCs expanded in PRP derived formulations maintain
pluripotency along the passages [71].
3.1.3. Chondrogenic differentiation
Differentiation is of paramount importance to cartilage regeneration. Differentiated cells
synthesize specific molecules unique to hyaline cartilage ECM, such as type 2 collagen and
aggrecans, in adequate proportion conferring exceptional biomechanical properties to the
ECM. Noteworthy, an inflammatory synovial fluid hinders the differentiation of human
subchondral progenitor cells, decreasing the expression of aggrecan, type 2 collagen and
cartilage oligomeric matrix protein [74]. However, PRP stimulates migration and differentia‐
tion of human subchondral cells into chondrocytes highlighting the consequences of manip‐
ulating the biological milieu.
Whether PRP drives the cell to chondrogenic differentiation in vitro depends on the precursor
cell characteristics along with the culture system (i.e. monolayer culture, micromass, 3-D
scaffolds).
Proteomic studies demonstrated that chondrocytes cultured with PRP in either mono- or 3D
conditions maintained the chondrocyte phenotype or at least de-differentiation was inhibited
after several days in culture [75].
3.2. Clinical trials
Conservative management of musculoskeletal conditions with PRP is becoming increasingly
popular; however, clinical evidence is preliminary and limited. At present, PRP is an investi‐
gational product. However, to advance PRP the International Cellular Medical Society (ICMS)
has developed guidelines for the handling and delivery of PRP and safety recommendations.
The final goal is to assist physicians in performing safe therapies. Absolute contraindications
for PRP administration include platelet dysfunction syndrome, critical thrombocytopenia,
hemodynamic instability, septicemia, local infection at the site of the procedure and patient
unwilling to accept risks.
OA is one of the most common indications for PRP injections. Most studies focus on knee OA
[76-78], but there are two case series on hip OA and a prospective cohort on osteochondral
lesions in the ankle [59]. These studies, merely aiming to demonstrate a clinically meaningful
result (e.g., pain relief and functional improvement), have used patient-reported outcomes as
end points (WOMAC, KOOS, IKDC and VAS). Importantly, clinical studies performed thus
far have strongly supported the safety of PRP (no infections, worsened outcomes, or serious
complication have been reported). The fact that PRP is not a potentially harmful experimental
treatment is corroborated by clinical studies in other conditions and medical fields [60].
Two systematic reviews with quantitative synthesis [79] and meta-analysis [80] have evaluated
the efficacy of PRP in the treatment of symptomatic knee OA [79] and the effectiveness of PRP
injections for treating knee joint cartilage degenerative pathology [80]. The former study
included six controlled studies (level I and II) including a total of 577 patients, 264 patients in
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the experimental PRP treatment. Pooled data using the WOMAC showed that PRP was better
than HA injections. Similarly, pooled IKDC scores favored PRP treatment. The authors
concluded that as compared with HA, multiple sequential PRP injections are beneficial for
patients with mild to moderate OA at six months follow-up.
The latter study [80] was less restrictive in the inclusion criteria and included eight single-arm
studies, three controlled cohorts and five randomized controlled trials with a total of 1543
patients. They compared the PRP group pooled values with the pre-treatment values and the
control groups treated with HA or placebo. PRP injections showed continual efficacy up to 12
months. The benefits of PRP lasted more than HA. Injection doses equal or less than 2 lead to
uncertainty in the therapeutic effects. Regarding knee severity, stratified analysis showed
better results at six months in the degenerative chondropathy group (effect size: 3.90, 95%; CI:
2.54-5.26) compared with advanced OA (effect size: 1.59, 95%; CI: 0.85-2.32).
Similar findings were reported in young active patients with osteochondral lesions in the talus
[59], while a comparative study in hip OA failed to show any difference between PRP and HA,
after 12 months follow-up [81]. Unfortunately, a comparison between these studies is difficult
due to different affected joints, differences between products, protocols and outcome meas‐
ures. Indeed, as pointed out in a recent excellent review [76], several variables can interfere,
such as the preparation method, the needle gauge for blood harvest and injection, the platelet
concentration, storage, pre-activation and granule secretion, the leukocyte concentration, the
anticoagulant and local anesthetic use, the blind or ultrasound-controlled injection, the
injection volume and frequency, the disease type and severity, and patient-specific factors. For
example, pure PRP and L-PRP formulations are not comparable with each other in terms of
leukocyte content, platelet count and plasma volume. Moreover, the platelet and leukocyte
concentration of the final L-PRP product can vary by as much as 100% [59]. Whether the
differences in the clinical results are secondary to the differences in the formulation requires
clarification. Similar improvements in pain and function have been observed in patients
treated both with PRP and L-PRP, albeit L-PRP caused more swelling and post-injection pain
[60]. It is worth mentioning that in these studies, storage of L-PRP introduces additional
variability of the final product [59,60]. Regarding administration procedures, the volume and
number of injections is empirically determined for each study. Although most studies involve
three injections, the period between the injections is variable, ranging from 1 to 4 weeks. In
knee OA, PRP is generally injected into the femoro-tibial compartment, although Sampson [82]
injected PRP into the suprapatellar bursa and reported increased cartilage thickness in 6 out
of 13 patients (46%). Theoretically, PRP application would be much more efficacious in patients
with early post-traumatic OA before the radiographic signs become severe, but this needs
further confirmation. In patients with significant irreversible bone and cartilage damage, the
effect of PRPs would most likely be less impressive, even so, PRP therapy probably would still
improve the patients’ quality of life. Whether frequent PRP administration can delay OA
progression and replacement surgery in patients with advanced OA may be a plausible
hypothesis, but long-term studies using surrogate end points such as WOMAC reduction and
refined imaging and biochemical markers potentially predictive of the delay of OA progression
are required.
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4. Hyaluronic acid and platelet rich plasma association
4.1. PRP+HA: A pericellular bioactive scaffold
It is conceivable that HA facilitates the molecular pool released from PRP to reach the target
cells by creating a pericellular bioactive scaffold around the cells. This pericellular matrix may
facilitate molecular diffusion and also adequate presentation of cytokines to their transmem‐
brane receptors located in the cytoplasmic membrane of the target competent cell. Moreover,
because the synovium is more cellular than the cartilage or the meniscus, and the ECM is looser,
the signaling molecules will diffuse and reach the synovial cells easier. In doing so the
molecular signaling pool released from PRP will reach mainly synovial cells before being
degraded. Therefore molecules released from PRP will reach primarily the synovial cells and
change their secretory pattern. The latter are responsible for creating the biological conditions
within the joint.
Instead, cartilage has a tightly packed ECM. Although signaling molecules such as cytokines
and GFs have low molecular weight, are water-soluble and diffuse easily, the number of cell
targeted may be much lower than in the synovium.
Another advantage of HA+PRP is facilitation of cells division and migration as this is a
common hallmark of matrices that are rich in HA. This is relevant since MSCs have been
identified in the synovium and in the synovial fluid.
Assuming that we target synovial cells and MSCs from the synovial niche, whether HMW or
LMW is optimal to be mixed with PRP should be investigated in the laboratory.
4.2. How PRP+HA injections may work?
Recent basic research supports the idea that HA and PRP treatments can be advantageously
associated without altering the original relevant characteristics of both products. Recently, in
a co-culture model, involving synovial cells and chondrocytes, Sundman et al. [83] compared
the effects of PRP or HA on inflammation, as measured by TNF-α, IL-6 and IL-8 proteins; they
found that, although both treatments decreased TNF-α production, IL-6 was decreased only
in HA cultures, but not in PRP treated cells, suggesting that both treatments influence
inflammation through different mechanisms. The expression of catabolic enzymes such as
metalloproteinases was reduced in synoviocytes and chondrocytes treated with PRP but not
in cells treated with HA. Moreover, the synoviocytes treated with PRP but not those treated
with HA expressed HAS-2. Thus, separately, HA and PRP are beneficial for joint cells although
they function through different mechanisms. Therefore, we may infer that their advantages
might be additive when both products are injected. Anitua et al. [66] evaluated the potential
of pure PRP to induce tendon cells and synovial fibroblasts migration and examined whether
the combination of PRP with HA improves their motility in vitro. Human fibroblast cells were
isolated from synovium and tendon biopsies and cultured by standard procedures. Therefore,
PRP was obtained from a young healthy donor and added to the culture medium at different
doses. Finally, the migratory capacity induced by PRP, HA, and both in association were tested.
PRP stimulated the migration of fibroblasts, as well as HA, but this effect was more prominent
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when HA was combined with PRP. Indeed, an increase of 335% in motility was observed in
the case of HA+PRP treatment compared with HA. Therefore, this in vitro study definitely
proves that PRP improves the biological properties of HA. CD44 has been implicated in the
migratory signal transduction, as well as receptor for HA-mediated motility in several cell
lineages. Plasma derived GFs increase the CD44 expression, and this favors cell migration
though the interaction of this receptor with extracellular HA. In another study [84], the
outgrowth of rabbit chondrocytes from cartilage fragments, loaded onto a composite scaffold
made of a HMW HA and autologous PRP, was evaluated. Defects were created by means of
a medial arthrotomy, in rabbit knees, and cartilage fragments were collected. Therefore,
membrane scaffolds with HA were prepared and cartilage fragments were loaded into the
membrane. Finally, the in vivo defects were filled with cartilage fragment load HA scaffolds
alone, or adding PRP. A histological evaluation at 6 months showed that this latter group had
better results, being filled by a repair tissue with some features of hyaline cartilage. This repair
tissue was better quality than that of the lesions treated with scaffold only and untreated
lesions.
The idea of positive interactions between HA and PRP is supported by an elegant experiment
where HA was added to GFs present in platelets. Bone morphogenetic protein (BMP) 2 plays
a critical role in the embryologic development of normal cartilage, thus it may enhance
reparative processes by setting in motion morphogenetic processes, including the formation
of ECM. Unfortunately, the high chondrogenic potency of BMP2 is hampered by its short half
life and rapid degradation in vivo. Perlecan/HSPG2, a heparan sulfate proteoglycan, represents
an essential component of cartilage ECM. Due to specific receptors Perlecan can act as a depot
for BMP2 storage and controlled kinetics, protecting BMP2 from proteolytic cleavage. To avoid
its own diffusion and susceptibility to degradation, PlnD1 was immobilized through conju‐
gation to a larger biocompatible carrier forming HA-based microgels (PlnD1-HA) in order to
preserve BMP2 activities [85]. The efficiency of this system was tested using an experimental
OA model in mice. It was observed that knees treated with PlnD1-HA/BMP2 had lesser
damage compared to control knees [86]. Moreover, they had, in comparison to controls treated
with Perlecan+HA, higher mRNA levels of type II collagen, proteoglycans, and xylosyltrans‐
ferase 1, a rate-limiting anabolic enzyme involved in the biosynthesis of glycosaminoglycans.
In conclusion, this study shows that HA can favor the stabilization of some GFs, enabling their
therapeutic potential.
A synergistic anabolic actions of HA and PRP has been also demonstrated in a 3D arthritic
neo-cartilage and ACLT-OA model. Indeed, the combination of HA+PRP can synergistically
promote cartilage regeneration and inhibit OA inflammation [87].
Currently, no clinical studies support this basic research. There are reports, which claim
excellent results of the HA+PRP association in Morton neuroma surgery [88] and in the healing
of pressure ulcers and surgical wounds [89,90]. However, these findings need confirmation by
controlled trials, because only one study [90] has assessed the superiority of the composite
PRP/HA in the treatment of pressure ulcers, in comparison with HA or PRP, used alone.
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The ability to understand and control the factors that play a role in the therapeutic effect of
HA+PRP shall guide the optimization and design of the combination i.e. optimal ratio,
molecular weight of HA, optimal PRP formulation.
5. Conclusions
OA is characterized by an impaired regeneration ability mainly attributed to an aberrant cycle
of cartilage degradation inducing synovial inflammation and protease activities that in turn
induce further joint catabolism. PRP+HA IA injections may break this vicious cycle skewing
the milieu towards anti-inflammatory and chondroprotective functions.
It is definitely proved that both HA or PRP alleviate symptoms in patients with mild-moderate
OA. Both treatment schedules most often involve repetitive injections, and are comparable in
terms of the route of administration and safety.
The concept behind HA application is to mimic the properties of synovial fluid, that is to
lubricate the hinge joint. Nevertheless, more recently, the idea that in homeostasis the synovial
fluid not only lubricates the joint but provides a positive biological micro-environment has
prompted research on HA signaling through hyaladherins located in the cell membrane.
Unfortunately, in OA, a deleterious fluidic micro-environment is already established, with the
presence of HA fragments, catabolic enzymes, and inflammatory molecules. In this context,
the central concept underlying IA injection is to modify this vicious circle. Alternatively, the
joint micro-environment can be modified with PRP injections that deliver multiple factors that
modulate angiogenesis and inflammation as well as cell anabolism. In fact, the relationships
between joint tissues (meniscus, synovium, ligaments, articular surface) and the synovial fluid
are bidirectional meaning that they both (the tissues and the synovial fluid) modify and are
modified. So, by injecting PRP and HA we aim to replace the ill-fluid with an “engineered
fluid” providing lubrication and able to control the delivery and presentation of signaling
molecules.
HA and PRP may improve OA symptoms through dissimilar biological mechanisms. Since
HA and PRP are not mechanical but biological approaches, the ability of PRP+HA to change
the biological status of the joint and promote tissue healing will be particularly critical during
the initial stages of OA, before the onset of structural changes. Although mixing HA and PRP
involves minimal manipulation, studies to verify critical aspects of the character and perform‐
ance of the composite are mandatory. Several key aspects such as the molecular weight of HA
and the concentration to be mixed with PRP should be analyzed. Ideally, HA tertiary structure
should let spaces through which molecules can diffuse, and approach the cell membrane to
interact closely with their specific receptors. Whether or not HA may help to retain PRP in the
joint cavity by exerting osmotic pressure on the joint surface calls for exploration. Considering
that the HA chains are constantly moving in solution, and that effective pores in this meshwork
will depend on HA concentration and MW, molecules may reach the articular surfaces with
different kinetics, depending on their size and hydrodynamic volumes. The future impact of
HA+PRP would depend on the capacity of delivering molecules that meet the requirements
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of the injured joint. An efficient IA therapy would be achieved if modulatory proteins released
from PRP+HA are capable of interfering with the catabolic micro-environment while modu‐
lating the inflammatory response, enhancing cell migration and proliferation, and controlling
the angiogenic status as well as cell differentiation. A new device capable to mix PRP with HA
in prefixed amounts is on the market. Un-published preliminary data suggest that this
combination is useful in the treatment of different forms of OA but only prospective random‐
ized double blind studies, preferably using both HA and PRP as comparators (three armed),
and a selected stage of OA severity, preferable early OA, will provide sound information about
the impact of this novel approach.
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